Please login to the form below

Not currently logged in


This page shows the latest Talen news and features for those working in and with pharma, biotech and healthcare.

Trial dents confidence in Sangamo’s gene-editing tech

Trial dents confidence in Sangamo’s gene-editing tech

alternative to other methods such as CRISPR and TALEN for in vivo gene editing.

Latest news

More from news
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Before CRISPR, the introduction of zinc-finger nucleases (ZFNs) and TALE nucleases (TALENs) in the genome engineering toolbox has already allowed gene manipulation in additional higher organisms such as human cells. ... TALENs work in a similar way to

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    But other technologies are still very much in play. Chief among these are zinc-finger nucleases (ZFNs), and transcription activator-like effector nucleases (TALEN). ... Cell therapy company Cellectis remains an exponent of TALEN, while Bluebird is using

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...